Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2001 September;26(3) > Minerva Endocrinologica 2001 September;26(3):181-92

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA ENDOCRINOLOGICA

A Journal on Endocrine System Diseases


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,383


eTOC

 

  NEW DIAGNOSTIC AND THERAPEUTIC STRATEGIES: SOMATOSTATIN ANALOGS. Part I


Minerva Endocrinologica 2001 September;26(3):181-92

Copyright © 2001 EDIZIONI MINERVA MEDICA

language: Italian

Somatostatin analogs in the clinical management of pituitary neoplasms

Colao A., Dorato M., Pulcrano M., Rossi F. W., Auriemma R. S., Lombardi G., Lastoria S.


PDF  


The medical approach to patients with secreting or clinically non-functioning pituitary adenoma as made considerable progress thanks to the use of new somatostatin analogs. They were first used to treat acromegaly in the mid 1980s and numerous studies have shown a reduction in GH concentration in over 90% of acromegalic patients. Good results were obtained using slow-release analog treatment also in TSH-secreting adenomas, whereas the therapeutic efficacy of these peptides in clinically non-functioning adenomas is still controversial. Treatment with somatostatin analogs improves symptoms, normalises hormone secretion and in some cases may induce a reduction in the volume of pituitary adenomas. Scintigraphy with octreotide may help to select patients who respond to this form of treatment.

top of page

Publication History

Cite this article as

Corresponding author e-mail